Topical Meclocycline Sulfonylactylate, Benzoyl Peroxide, and a Combination of the Two in the Treatment of Acne Vulgaris

ERIK BORGAND,1 BERIT KRISTENSEN2, BIRGITTA LARSSON-STYMNE,3 ANDERS STRAND NIELS K. VEIN and HENRY B. JAKOBSEN1

1Department of Dermatology, Välingby, 2Department of Dermatology, Centralsjukhuset, Karlstad, 3Department of Dermatology, Regionsjukhuset, Örebro, Sweden, 4Dermatology clinic, Minde, Norway, 5Department of Dermatology, University Hospital, Uppsala, Sweden, 6Dermatology clinic, Aalborg and 7Basoderm A/S, Denmark

One hundred and six patients with acne vulgaris of the face were treated for 10 weeks with either topical meclozine sulfonylactylate, topical benzoyl peroxide or both preparations. A randomized, double-blind parallel group study was used. Benzoyl peroxide proved more effective than meclozine in reducing acne lesion counts, while local side effects were more common in the benzoyl peroxide-treated patients. The combined treatment was of intermediate efficacy with fewer local side effects.

(accepted September 24, 1990)


E. Borglund, Dermatology clinic, Indalsbacken, S-162 22 Välingby, Stockholm.

Combined treatment with topical clindamycin and benzoyl peroxide and with topical erythromycin and benzoyl peroxide have shown advantages over treatment with either of the three agents alone (1, 2). Meclocycline sulfonylactylate is a tetracycline derivative developed for the topical treatment of acne vulgaris. In this study the three topical treatments of acne vulgaris: 1) meclozine sulfonylactylate, 2) benzoyl peroxide and 3) the combination of the two were compared.
MATERIAL AND METHODS
One hundred and six male and female acne patients with more than 10 papules and pustules in the face entered the study at six centers. Two patients were withdrawn and two were lost to follow-up. One hundred and two patients (48 males and 54 females; median age 19 years, range: 12-37 years) were available for evaluation. The duration of acne ranged from 2 months to 17 years. Systemic antibiotic treatment was discontinued at least one month before the trial and any topical treatment of the face was discontinued at least 2 weeks before initiation of the trial. No patient was included from mid March through the summer months in order to avoid the influence of natural sun exposure.

In a parallel group design 36 patients were treated with a water-based benzoyl peroxide 5% gel (Basilon®) twice daily, 33 patients with meclozocine sulfosalicylate 1% cream (Meclorol®) twice daily and 33 patients with Basiron in the morning and Meclorol in the evening. All patients were instructed only to treat in the morning during the first week and wash off the drug after 3 h for the first 3 days. This was done in order to limit the number of withdrawals due to initial skin irritation in the benzoyl peroxide-treated patients. The treatment period was 10 weeks. Treatment allocation was based upon block randomization, and all possible measures to double-blind the trial were taken. However, blinding was difficult due to differences in colour, odour, viscosity and side effects of the drugs that could not be masked without changing their properties.

Acne lesions were counted at baseline and after 2, 6 and 10 weeks of treatment; comedones in a circular area only (diameter = 5 cm) while the number of papules, pustules, nodules and cysts were counted in the entire face above the mandibular line. One investigator counted all acne lesions in the circular area only. Therefore, the counts of inflammatory lesions recorded for these 9 patients were very low and were not included in the efficacy analyses.

The non-parametric test of Kruskal and Wallis (3) was used to detect differences between treatment effects regarding the reduction in number of acne lesions. If differences between the treatments were detected, these treatments were compared employing Dunn's test (4). The investigators' and patients' ratings of efficacy and acceptability of treatments were compared by Chi-square test.

RESULTS
Two of the 106 patients enrolled in the study were lost to follow-up. Both were allocated to the combined treatment. Two patients were withdrawn, one due to pregnancy, and one due to protocol violation (preceding treatment stopped too late). The results of treatment of the remaining 102 patients are presented in Fig. 1. Basiron twice daily was more effective in reducing the number of acne lesions than Meclorol. The combined treatment was of intermediate efficacy. The average reduction of acne lesions obtained with benzoyl peroxide after 10 weeks was

*Acne Derm Venereol (Stockh) 71*
about 60%. The effects of treatments on the acne lesion counts were statistically significantly different after 2 weeks of treatment for comedones (Basiron more effective than Meclosorb in reducing comedone counts, p < 0.001, and Basiron more effective than the combination, p < 0.05) and papules (Basiron more effective than Meclosorb, p < 0.001, and the combination more effective than Meclosorb, p < 0.01) and after 10 weeks for comedones only (Basiron more effective than Meclosorb, p < 0.01, and the combination more effective than Meclosorb, p < 0.05). Nodules and cysts were seen too infrequently to give an impression of treatment effect on these lesions. The overall ratings of efficacy by investigators and patients were similar and in accordance with the effects on acne lesion counts. The ratings of efficacy by the investigators were good to excellent in 63% of the benzoyl peroxide-treated patients, in 36% of the meclozycine-treated patients and in 67% of the patients who received the combined treatment. The corresponding ratings by the patients in the three treatment groups were 63%, 49% and 55%, respectively.

Before treatment erythema was present in 37% and scaling in 28% of the patients. During treatment erythema initially increased slightly among the patients who received treatment with benzoyl peroxide, while a decrease was observed in the group treated with meclozycine or the combination. Scaling was increased in the group treated with benzoyl peroxide alone. Stinging and/or burning, usually mild was reported by 50% of the patients who received only benzoyl peroxide therapy, much less frequently in the group receiving the combined treatment. A yellowish discoloration of the skin was reported in two patients treated with meclozycine alone and in one patient treated with the combination. Yellowish discoloration of the skin was also reported for one patient treated only with benzoyl peroxide. One case of allergic contact dermatitis to benzoyl peroxide, confirmed by patch testing was reported in this group. Five patients stopped treatment prior to the completion of the trial, three patients because of local side effects of benzoyl peroxide, two because of unsatisfactory progress during treatment with meclozycine.

DISCUSSION
In this study meclozycine proved less effective than benzoyl peroxide in reducing the average acne lesion counts during 10 weeks of treatment. The reduction attained with benzoyl peroxide after 10 weeks was in accordance with the results reported by others (1, 5, 6), whereas the results obtained with meclozycine were inferior to those obtained by Hjorth et al. (7). The efficacy of the combined treatment was between that of either component alone and erythema and scaling was reduced. These side effects are frequent during the first weeks of treatment with benzoyl peroxide (8, 9). The presence of erythema in 37% and of scaling in 28% of the patients even before treatment is remarkable. The yellowish discoloration caused by meclozycine in some patients is the main side effect noted for this drug. The discoloration is completely reversible. It is quite obvious that the two drugs tested have properties that may cause very different local side effects. The reported case of discoloration in the benzoyl peroxide group indicates that some degree of blinding was obtained, probably due to the inclusion of the patients in combined treatment.

Topical antibiotic treatment seems to be more effective if combined with benzoyl peroxide (1, 2). Meclozycine seems less suitable for such treatment combination than clindamycin and erythromycin. So far neither meclozycine nor clindamycin or erythromycin have proved to be more effective than benzoyl peroxide alone (9), but for acne patients susceptible to skin irritation from benzoyl peroxide the combined treatment with benzoyl peroxide and one of these topical antibiotics is advantageous.

ACKNOWLEDGEMENTS
We are grateful to Basotherm GmbH, biometric department for statistical work-up of the data and to A. Bergqvist-Karlsson, Akademiska sjukhuset, Uppsala, for helpful discussions of the study protocol.

REFERENCES
Langerhans’ Cell Histiocytosis in an Adult

B. LINDELOF1,2, B. FORSLIND3, M. HILLIGES2, O. JOHANSSON3, and L. ÅSTRÖM4

1Department of Dermatology, and 2Department of Pediatrics, Karolinska Hospital, 3Department of Medical Biophysics, Experimental Dermatology Unit, Department of Histology and Neurobiology, Karolinska Institute, Stockholm, Sweden

A woman with typical skin lesions of histiocytosis X is reported. Electron microscopic and immunohistochemical investigations revealed a large number of markedly long Birbeck Langerhans’ cell granulæ. During treatment with Interferon α-2b, the patient developed infarctus cerebri and died. Key words: Histiocytosis X; Electron microscopy; Immunohistochemistry.

(Accepted October 1, 1990.)


B. Lindelöf, Department of Dermatology, Karolinska Hospital, S-104 01 Stockholm, Sweden.

Histiocytosis X (1) is a proliferative disorder of specialized cells containing distinctive cytoplasmic structures characteristic of Langerhans’ cells (2). Cutaneous lesions often occur. We present a fatal case of histiocytosis X with adult onset.

CASE REPORT

A 33-year-old woman had had diffuse redness, scaling and crusting of the skin of the scalp, axillae, and inguinal region since the age of fifteen (Fig. 1). Since the age of twenty, she had also had inflammation, swelling and necrosis of gingival tissue in the mouth and had been followed up by several dermatologists. When she was 24 years old, a gingival biopsy specimen showed typical changes resulting from histiocytosis X. No systemic involvement has occurred and roentgenographic examinations of the chest and osseous system as well as scintillation scanning of the liver have not given any clear evidence of extension of the disease to these sites. Neither have there been any signs of lymph node enlargement, hepatosplenomegaly or manifest diabetes insipidus.

Fig. 1. Distinctive skin lesions in the patient with histiocytosis X.